ライフサイエンスコーパス: leiomyosarcoma

1 trial in a more homogeneous population (eg, leiomyosarcoma).

2 the malignant progression from leiomyoma to leiomyosarcoma.

3 l features resembling those of leiomyoma and leiomyosarcoma.

4 rgically unresectable uterine or soft-tissue leiomyosarcoma.

5 rch is already underway with this concept in leiomyosarcoma.

6 yed smooth muscle differentiation similar to leiomyosarcoma.

7 rst-line treatment in patients with advanced leiomyosarcoma.

8 at included 26 primary specimens of vascular leiomyosarcoma.

9 outcomes for patients with primary vascular leiomyosarcoma.

10 ic therapies did not impact LR, DM, or OS of leiomyosarcoma.

11 s received a confirmed diagnosis of vascular leiomyosarcoma.

12 posarcoma, dedifferentiated liposarcoma, and leiomyosarcoma.

13 ent age was 54.0 (21-77 years); 42 (34%) had leiomyosarcoma.

14 or second-line therapy for advanced uterine leiomyosarcoma.

15 ine sarcoma, especially in those with occult leiomyosarcoma.

16 or second-line therapy for advanced uterine leiomyosarcoma.

17 vulva, and 1 multiple Epstein-Barr virus(+) leiomyosarcoma.

18 re malignant transformation of UL to uterine leiomyosarcoma.

19 d favorable results in patients with uterine leiomyosarcoma.

20 ntestinal stromal tumors or gastrointestinal leiomyosarcomas.

21 responses were noted in 17 patients with GI leiomyosarcomas.

22 were found in gastrointestinal leiomyomas or leiomyosarcomas.

23 ohistochemically from typical leiomyomas and leiomyosarcomas.

24 tant bands were found in 3 leiomyomas and 11 leiomyosarcomas.

25 here were no mutations in 3 leiomyomas and 4 leiomyosarcomas.

26 scle and a series of primary retroperitoneal leiomyosarcomas.

27 s of the skin, anal carcinoma, and pediatric leiomyosarcomas.

28 inferior vena cava and account for 5% of all leiomyosarcomas.

29 rm of chromosome 1, clustered with malignant leiomyosarcomas.

30 upregulation of downstream effectors in most leiomyosarcomas.

31 ression are up-regulated in high-grade human leiomyosarcomas.

32 omas, carcinosarcomas, stromal sarcomas, and leiomyosarcomas.

33 omosomes 15, 18, 21, and X was infrequent in leiomyosarcomas (1 of 6 tumors for each chromosome) and

34 lymphoblastic leukemia, 1 Hodgkin disease, 8 leiomyosarcoma, 1 hepatoblastoma, and 1 schwannoma.

35 ell tumors, 2 of 3 synovial sarcomas, 4 of 4 leiomyosarcomas, 1 of 1 malignant fibrous histiocytoma,

36 ted pleomorphic sarcoma (18.8 +/- 13.1), and leiomyosarcoma (15.2 +/- 10.2).

37 The predominant histological subtypes were leiomyosarcoma (22 [26%]) and liposarcoma (16 [19%]).

38 revalent histologies were liposarcoma (50%), leiomyosarcoma (26%), and malignant fibrous histiocytoma

39 Leiomyosarcoma (AAIR 0.14 cases/1 million) and malignant

40 Four of 10 patients with non-GI leiomyosarcomas achieved a partial response.

41 d stage I, II, III, or IV high-grade uterine leiomyosarcoma, adjuvant treatment with gemcitabine-doce

42 ine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline

43 n patients who have advanced liposarcoma and leiomyosarcoma after they experience failure of prior ch

44 hour trabectedin regimen in liposarcomas and leiomyosarcomas, although the qwk 3-hour regimen also de

45 Leiomyosarcoma and angiosarcoma may occur disproportiona

46 Patients with advanced leiomyosarcoma and anthracycline-naive were eligible.

47 lished treatment option for advanced uterine leiomyosarcoma and has demonstrated efficacy in nonleiom

48 ent-naive patient who has metastatic uterine leiomyosarcoma and has experienced complete tumor remiss

49 models for the prediction of retroperitoneal leiomyosarcoma and liposarcoma type and histological gra

50 stological type and grade in retroperitoneal leiomyosarcoma and liposarcoma.

51 ase at presentation, the histologic subtypes leiomyosarcoma and malignant peripheral-nerve tumor, mic

52 ng equipoise, in the role of chemotherapy in leiomyosarcoma and the value of CR in liposarcoma.

53 We examined archival materials from 16 leiomyosarcomas and 13 benign leiomyomas by polymerase c

54 patients with STS (17 gastrointestinal [GI] leiomyosarcomas and 39 other histologies) were treated o

55 tudied, LOH on chromosome 10 was frequent in leiomyosarcomas and absent in benign leiomyomas.

56 ly regulated in selected human tumors (e.g., leiomyosarcomas and colorectal cancer) by methylation of

57 ellite instability was found infrequently in leiomyosarcomas and not detected in leiomyoma.

58 ymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusively in GISTs (21%)

59 /ERBB2-negative breast cancer, 1 had uterine leiomyosarcoma, and 1 had oncocytic parotid gland carcin

60 n prostate cancer, liver cancer, soft tissue leiomyosarcoma, and glioblastoma multiforme.

61 ignancies, including fibrosarcoma, leukemia, leiomyosarcoma, and myxosarcoma, which are unusual in p5

62 location, recurrent disease at presentation, leiomyosarcoma, and nonliposarcoma histology were indepe

63 sted of scrotal wall liposarcoma, epididymal leiomyosarcoma, and recurrent spindle cell malignancy of

64 ients, one with cholangiocarcinoma, one with leiomyosarcoma, and three with non-small-cell lung cance

65 ms' tumors, rhabdomyosarcomas, liposarcomas, leiomyosarcomas, and adrenal cortical carcinomas.

66 grade undifferentiated pleomorphic sarcomas, leiomyosarcomas, and carcinosarcomas that widely recapit

67 isease subtype-specific groups (liposarcoma, leiomyosarcoma, angiosarcoma, undifferentiated pleomorph

68 Leiomyosarcomas appear causatively linked to EBV, wherea

69 Vascular leiomyosarcomas are a rare subtype of leiomyosarcomas th

70 Vascular leiomyosarcomas are aggressive malignant tumors, with hi

71 Here, we have chosen leiomyosarcoma as a model for examining the relationship

72 alignant tumors derived from the myometrium (leiomyosarcomas), (b) is overexpressed in tumor-associat

73 hways, we analyzed the expression profile of leiomyosarcomas by DNA microarray analysis.

74 lung cancer, skin cancer, germ cell tumors, leiomyosarcomas, cancers of the head and neck, conjuncti

75 nal AGS protein (AGS4) from a human prostate leiomyosarcoma cDNA library.

76 show that HGF/SF-Met signalling in the human leiomyosarcoma cell line SK-LMS-1 enhances its in vivo t

77 tive form of Stat3, Stat3beta into the human leiomyosarcoma cell line SK-LMS-1.

78 f conditioned medium from the SK-LMS-1 human leiomyosarcoma cell line.

79 n of ITGA7 expression in prostate cancer and leiomyosarcoma cell lines suppressed tumor growth and ce

80 , U373 and SNB19), as well as SK-LMS-1 human leiomyosarcoma cells are also sensitive to fM-GAi; (2) f

81 Ectopic overexpression of TIMP-3 in cultured leiomyosarcoma cells conferred an epithelial morphology,

82 In experiments with human SK-LMS-1 leiomyosarcoma cells, we show that the Akt kinase is act

83 The signatures substantially recover the leiomyosarcoma, dedifferentiated liposarcoma (DDLPS), an

84 Fibrosarcoma, leiomyosarcoma, dedifferentiated, and myxoid liposarcoma

85 In contrast, the monthly death rate after leiomyosarcoma diagnosis increased from 5% in the first

86 emic myocardium, human heart, and a prostate leiomyosarcoma for entities that activated G protein sig

87 d there is loss of the wild-type allele in a leiomyosarcoma from the proband.

88 Distinction of malignant uterine leiomyosarcomas from benign leiomyomas by morphological

89 pathway in smooth muscle transformation and leiomyosarcoma genesis, and support treatment of selecte

90 nt and quantitative method for assessment of leiomyosarcoma grade and mitotic activity thereby render

91 oma, lipoma, gastrointestinal stromal tumor, leiomyosarcoma, granular cell tumor).

92 0.40-0.97) while patients with G3 DDLPS and leiomyosarcoma had not.

93 Interestingly, 8 of 14 (57.2%) informative leiomyosarcomas had LOH for at least one marker on chrom

94 several human diseases, notably soft tissue leiomyosarcoma, hepatocellular carcinoma, and hematologi

95 of tumor necrosis or distant metastases and leiomyosarcoma histiotype (multivariable p < 0.05 each).

96 tumors (HR, 1.60; 95% CI, 1.03 to 2.49) and leiomyosarcoma (HR, 2.67; 95% CI, 1.22 to 5.85) but not

97 kemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients.

98 nd patient-derived xenograft liposarcoma and leiomyosarcoma in mice, improve median 90- or 200-day re

99 dentified in association with an outbreak of leiomyosarcoma in the swim bladders of Atlantic salmon.

100 detected in the tumor cells in 85 and 88% of leiomyosarcomas in HIV-infected people and transplant re

101 herapy was used consistently infrequently in leiomyosarcoma (IQR 13% [0%-13%].

102 Uterine leiomyosarcoma is the most common subtype of uterine sar

103 After NHL, leiomyosarcoma is the second leading cancer in children

104 letely resected, uterine-limited, high-grade leiomyosarcoma is under investigation.

105 Histologic types other than leiomyosarcoma, liposarcoma, and myxofibrosarcoma were a

106 human sarcoma cells, including fibrosarcoma, leiomyosarcoma, liposarcoma, synovial sarcoma, and neuro

107 advances in the diagnosis of the more common leiomyosarcoma (LMS) anatomic variants, potentially usef

108 Leiomyosarcoma (LMS) is a mesenchymal cancer that occurs

109 Leiomyosarcoma (LMS) is a soft tissue tumor with a signi

110 Leiomyosarcoma (LMS) is a tumor of smooth muscle that ca

111 Leiomyosarcoma (LMS) is one of the most common subtypes

112 Uterine leiomyosarcoma (LMS) is staged by the modified Internati

113 ing the dissemination of unsuspected uterine leiomyosarcoma (LMS) throughout the pelvis of a physicia

114 of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma (LMS), a subtype of soft tissue sarcoma t

115 Management of uterine sarcomas including leiomyosarcoma (LMS), endometrial stromal sarcoma, high-

116 mal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature myogenic differentiation.

117 Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progress

118 es: high-grade myxoid liposarcoma (HG-MLPS); leiomyosarcoma (LMS), synovial sarcoma (SS), malignant p

119 dacarbazine (DTIC) in patients with advanced leiomyosarcoma (LMS).

120 tients with recurrent and metastatic uterine leiomyosarcoma (LMS).

121 ates with poor prognosis in nongynecological leiomyosarcoma (LMS).

122 vestigations impacting management of uterine leiomyosarcoma (LMS).

123 Leiomyosarcomas (LMS) are genetically heterogeneous tumo

124 remains in the differentiation of GIST from leiomyosarcomas (LMSs).

125 In contrast to leiomyosarcomas, LOH for chromosome 10 was not found in

126 In the subset of women with leiomyosarcoma, LSH/LM was associated with an increased

127 histopathologies: fibrosarcoma, liposarcoma, leiomyosarcoma, malignant fibrous histiocytoma, or synov

128 mprising angiosarcomas (AS), Ewing sarcomas, leiomyosarcomas, malignant peripheral nerve sheath tumor

129 posarcoma (median 0%), with higher rates for leiomyosarcoma (median 10%) with high variation (IQR 26%

130 larly bone and soft tissue sarcomas, uterine leiomyosarcoma, melanomas, and radiotherapy-related cent

131 diagnoses were myxofibrosarcoma (n = 22) and leiomyosarcoma (n = 20).

132 No patients with leiomyosarcoma (n=10) had an objective response.

133 Leiomyosarcomas (n = 101) were the most frequently repor

134 ing (n = 13), one fibrosarcoma (n = 12), six leiomyosarcomas (n = 29), seven liposarcomas (n = 31), t

135 ll as a few tumors of a second type (uterine leiomyosarcoma) not previously associated with this tran

136 We report a case of primary low-grade leiomyosarcoma of the mandible in an otherwise healthy y

137 t (four malignant fibrous histiocytomas, two leiomyosarcomas, one pleomorphic rhabdomyosarcoma, one d

138 d older than 18 years with confirmed primary leiomyosarcoma or liposarcoma proceeding to surgical res

139 enetic or molecular genetic abnormalities in leiomyosarcomas or leiomyomas and surveyed chromosomes 7

140 Eleven children (17%) had leiomyosarcomas (or leiomyomas), which are otherwise exc

141 d in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarcomas, malignant

142 activity of this regimen in advanced uterine leiomyosarcoma, other soft-tissue sarcomas, and pediatri

143 e the role of aberrant PI3K-AKT signaling in leiomyosarcoma pathogenesis, we genetically inactivated

144 nificantly associated with worse survival in leiomyosarcoma patients (n = 165, p = 0.007, FDR = 0.06)

145 a pleomorphic mesenchymal tumor, probably a leiomyosarcoma, rather than an epithelial tumor.

146 ly de-differentiated liposarcoma and uterine leiomyosarcoma remains unsatisfactory, despite intensive

147 was identified in Oncopig STS cell lines and leiomyosarcomas, respectively.

148 tutive mTOR activation was restricted to the leiomyosarcomas, revealing the requirement for additiona

149 Leiomyosarcoma risk was significantly increased for surv

150 ncopig STS cell line (fibroblast) and tumor (leiomyosarcoma) RNA-seq data to compare Oncopig and huma

151 patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overa

152 Treatment of well-established leiomyosarcoma SKLMS-1 and rhabdomyosarcoma RD xenograft

153 Restoration of wt p53 expression in human leiomyosarcoma SKLMS-1 cells that contain mutant p53 mar

154 This established the diagnosis of leiomyosarcoma; subsequently, an en bloc resection of ma

155 motherapy in liposarcoma and radiotherapy in leiomyosarcoma, suggesting agreement between centres.

156 cancer, squamous cell cancer, lymphoma, and leiomyosarcoma, suggesting that the decreased expression

157 scular leiomyosarcomas are a rare subtype of leiomyosarcomas that most commonly affect the inferior v

158 These results suggest, that for leiomyosarcoma, the degree of fatty acyl unsaturation ma

159 Leiomyosarcomas typically have complex cytogenetic abnor

160 r cells, including the lines SK-LMS-1 (human leiomyosarcoma), U118 (human glioblastoma), and DU145 (h

161 Uterine leiomyosarcoma (ULMS) is a rare gynecologic malignancy w

162 Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-t

163 ive response in 35% of patients with uterine leiomyosarcoma (uLMS).

164 ghly aggressive and pleomorphic tumors named leiomyosarcomas (ULMS).

165 months (range, 1 day to 89 months) and after leiomyosarcoma was 12 months (range, 10 days to 19 month

166 Development of leiomyosarcoma was significantly more common after AA pl

167 Within leiomyosarcomas, we identify three proteomic subtypes wi

168 Liposarcoma and leiomyosarcoma were associated with late recurrence and

169 Leiomyosarcomas were reported with two age peaks, in chi

170 all female animals developed massive uterine leiomyosarcomas, whereas practically all males exhibited

171 ing patients with metastatic or unresectable leiomyosarcoma who had not received chemotherapy previou

172 -grade or high-grade advanced liposarcoma or leiomyosarcoma who had received at least two previous sy

173 tinguish gastrointestinal stromal tumor from leiomyosarcoma with high sensitivity and specificity.

174 smooth muscle cell hyperplasia and abdominal leiomyosarcomas, with a very rapid onset and elevated in